Mucinoses

Queen Latifah and Bernie Williams star in "Beyond Breathless" documentary on A&E

Retrieved on: 
Monday, November 30, 2020
Organ systems, Medicine, Clinical medicine, Autoimmune diseases, Mucinoses, Idiopathic pulmonary fibrosis, Systemic scleroderma, Scleroderma, Boehringer Ingelheim, IPF, Pulmonary fibrosis, Fibrosis

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8814751-boehringer-ingelheim-bey...

Key Points: 
  • Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8814751-boehringer-ingelheim-bey...
    "My mom struggled with scleroderma especially after it progressed to her lungs and that made it difficult for her tobreathe," said Queen Latifah.
  • My hope is that for those living with this disease or caring for someone they love that they know they're not alone in this fight."
  • Idiopathic pulmonary fibrosis (IPF) and scleroderma-associated ILD, also known as systemic sclerosis-associated ILD (SSc-ILD), are two common types of ILD.
  • "When my dad was diagnosed with IPF a type of ILD we had never heard of it before," said Bernie Williams, who narrates the documentary.

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

Retrieved on: 
Tuesday, November 24, 2020
Organ systems, Medical specialties, Medicine, Autoimmune diseases, Mucinoses, Rheumatology, Systemic scleroderma, Pulmonary fibrosis, Idiopathic pulmonary fibrosis, Scleroderma, Fibrosis

The Company is developing such a molecule as IBIO-100 for the treatment of fibrotic disorders, including systemic scleroderma and idiopathic pulmonary fibrosis.

Key Points: 
  • The Company is developing such a molecule as IBIO-100 for the treatment of fibrotic disorders, including systemic scleroderma and idiopathic pulmonary fibrosis.
  • The 392 Patent contains 19 claims and expires in June 2036.
  • iBio plans to conduct IND-enabling studies on IBIO-100 in 2021.
    iBio is a global leader in plant-based biologics manufacturing.
  • Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for infectious diseases.

Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Organ systems, Autoimmune diseases, Clinical medicine, Immunology, Mucinoses, Systemic scleroderma, Autoimmunity, Multiple sclerosis

Systemic sclerosis is a rare, life-threatening autoimmune disease affecting up to 75K Americans

Key Points: 
  • Systemic sclerosis is a rare, life-threatening autoimmune disease affecting up to 75K Americans
    Norwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today presented additional data from the RESOLVE-1 Phase 3 study of lenabasum for the treatment of systemic sclerosis.
  • We believe these findings offer a rationale for additional clinical development of lenabasum, a non-immunosuppressive agent, that could address lung function decline in systemic sclerosis patients.
  • The Company is continuing to analyze the data and will consider the potential for an additional study based on results of these analyses.
  • Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.

H2 2020 Systemic Sclerosis (Scleroderma) - Pipeline Review - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 28, 2020
Health, Pharmaceutical, Organ systems, Autoimmune diseases, Mucinoses, Medicine, Anatomy, Systemic scleroderma, Pipeline, Drug pipeline, Systemic, Sclerosis, Scleroderma

The "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The publisher's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Systemic Sclerosis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Immunology) pipeline depth and focus of Indication therapeutics.

Bob Saget and Susan Feniger host the first global edition of Cool Comedy - Hot Cuisine, raising $1.1M for the Scleroderma Research Foundation

Retrieved on: 
Tuesday, October 20, 2020
Medical specialties, Autoimmune diseases, Organ systems, Clinical medicine, Mucinoses, Scleroderma Research Foundation, Bob Saget, Scleroderma, Systemic scleroderma

With many personal stories of how scleroderma has impacted their lives, each guest helped to amplify the vital work of SRF and itscommitment to finding a cure.

Key Points: 
  • With many personal stories of how scleroderma has impacted their lives, each guest helped to amplify the vital work of SRF and itscommitment to finding a cure.
  • As Bob Saget explains, his commitment is very personal;"I fortuitously became involved with the Scleroderma Research Foundation in 1992.
  • All funds raised benefit theScleroderma Research Foundation, and advance online registration to watch this unforgettable evening is required.
  • The word scleroderma literally means "hard skin," but the disease is much more, often affecting the internal organs with lethal consequences.

New medical software powered by AI aids diagnosis of autoimmune diseases

Retrieved on: 
Thursday, September 24, 2020
Medical specialties, Organ systems, Angiology, Clinical medicine, Autoimmune diseases, Mucinoses, RTT, Rare diseases, Scleroderma, Microcirculation, Capillary, Rheumatology

By looking at capillaries, doctors can assess the health of the patient's blood circulation, find abnormal capillaries, capillary loss, etc.

Key Points: 
  • By looking at capillaries, doctors can assess the health of the patient's blood circulation, find abnormal capillaries, capillary loss, etc.
  • which can lead to conditions such as scleroderma and dermatomyositis.
  • This is the first tool, in internal medicine and rheumatology, to offer automation advantages to capillaroscopy, a well established technique that lacked proper tools.
  • We can obtain reports with clinical parameters quickly and easily that guide us in the diagnosis, for example, of diseases such as scleroderma, by studying the microcirculation of the capillaries near the base of the patient's nail".

Europe Scleroderma Market and Competitive Landscape Report 2020: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 21, 2020
Health, Pharmaceutical, Autoimmune diseases, Mucinoses, RTT, Scleroderma, Medical specialties, Clinical medicine, Medicine

The "Europe Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Scleroderma Market and Competitive Landscape - 2020, provides comprehensive insights into the Scleroderma pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Scleroderma market size and drug sales.
  • Scleroderma pipeline: Find out drugs in clinical trials for the treatment of Scleroderma by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Scleroderma drugs: Identify key drugs marketed and prescribed for Scleroderma in the US, including trade name, molecule name, and company
    Scleroderma market valuations: Find out the market size for Scleroderma drugs in 2019 by countries.

United States Scleroderma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 18, 2020
Pharmaceutical, Health, Other Health, Autoimmune diseases, Organ systems, Business, Articles, Mucinoses, RTT, Scleroderma, Market share, Market analysis, Market

The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Scleroderma Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Scleroderma pipeline products, Scleroderma epidemiology, Scleroderma market valuations and forecast, Scleroderma drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Scleroderma treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Scleroderma products

Primary endpoint achieved with ziritaxestat  in NOVESA trial in systemic sclerosis patients

Retrieved on: 
Friday, September 11, 2020
Organ systems, RTT, Anatomy, Autoimmune diseases, Mucinoses, Health, Rare diseases, Connective tissue diseases, Systemic scleroderma, Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Clinical endpoint

Systemic sclerosis (SSc) affects approximately 124,000 people3 in the US and Europe4, with a predominance of female patients (>80%).

Key Points: 
  • Systemic sclerosis (SSc) affects approximately 124,000 people3 in the US and Europe4, with a predominance of female patients (>80%).
  • Patients recruited for NOVESA included mostly females (70%) around 50 years old, with a mean disease duration of 1.9 years.
  • 94% of patients (31 of the 33) who completed the NOVESA trial continued in the long-term open label extension trial.
  • We are excited to see that after showing promising activity in the phase 2 FLORA trial in idiopathic pulmonary fibrosis, ziritaxestat achieved statistically significant improvements in mRSS in diffuse SSc, the primary endpoint in the NOVESA study.

Philip J. Clements, MD, MPH, MACR, is recognized by Continental Who's Who

Retrieved on: 
Tuesday, August 25, 2020
Medical specialties, Autoimmune diseases, Cutaneous conditions, Organ systems, RTT, Syndromes, Mucinoses, Raynaud syndrome, Rheumatology, Scleroderma, David Geffen School of Medicine at UCLA

For nearly 50 years, he has garnered a well-deserved reputation for his vast repertoire of expertise and professional experience.

Key Points: 
  • For nearly 50 years, he has garnered a well-deserved reputation for his vast repertoire of expertise and professional experience.
  • He is devoted to educating future medical professionals as a Professor of Medicine for the David Geffen School of Medicine at UCLA.
  • As a Rheumatologist, he is a key opinion leader in Scleroderma and Raynaud's disease and has conducted many clinical trials.
  • He would also like to recognize his beautiful family his wife of 35 years, Ellie, and his children, Philip Jr, Annette, and David.